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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the effectiveness of dressings and securement devices for peripheral arterial catheters.
B A C K G R O U N D
Description of the condition
For a definition of technical terms, please see the Appendix 1 in
appendices.
Arterial catheters (ACs) are thin, flexible, plastic tubes that are
inserted through the skin into arteries to allow easy access to the
bloodstream for continuous blood pressure monitoring and regu-
lar blood sampling in emergency departments, operating theatres
and intensive care units (ICUs). Peripheral ACs are typically in-
serted into the radial (forearm), femoral (thigh), axillary/brachial
(upper arm) and dorsalis pedis (foot) arteries (Scheer 2002).Many
ACs are required to be inserted for only 24 to 48 hours, tomonitor
patients in the perioperative period after cardiac, liver and other
major surgeries. However, patients in the ICU may require ACs
for longer than 48 hours.
Catheter failure in ACs occurs if the catheter loses its function.
Catheters are always removed when function is jeopardised by
infectious or mechanical causes, and this triggers the need for a
replacement insertion of a new AC. The risk of catheter-related
bloodstream infection (CR-BSI) and other AC infections exists
because the insertion of an AC breaks the skin’s integrity, allowing
the potential entry of micro-organisms into the body (Hugonnet
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2004; Maki 2006; Safdar 2013). Micro-organisms gain access to
an AC by migration externally from the skin along the exterior
catheter surface or internally from the catheter hub (Donlan 2011;
Zhang 2016). The incidence of CR-BSI has been reported to range
from 0.59 to 1.7 per 1000 catheter days, and between 0.34% and
0.8% of intensive care patients develop an infection (Gowardman
2010; Lorente 2004; Maki 2006).
AC mechanical failure may be the result of arterial thromboses
(blood clots), with the potential for occlusion (blockage of blood
flow) to the distal limb, which in rare cases can lead to amputa-
tion of the limb or distal digits (fingers, thumbs or toes). Partial
movement of the AC may also result in blockage of the device and
resultant failure, because of a kinked catheter or the end of catheter
resting on the artery wall. This requires device removal and re-
placement, since inaccurate blood pressure measurements have the
potential for an undetected unstable patient (Scheer 2002). Dis-
lodgement may occur due to movement or pressure on the part of
the device that is external to the insertion site. In critical situations
following accidental removal, shock from rapid haemorrhage can
be catastrophic. Attributable costs for the care of a patient with a
CR-BSI from a vascular catheter average USD 45,000 (O’Grady
2002), but can range between USD 3000 and USD 60,536 (Raad
2007; Schwebel 2012), and are likely to be significant in ACs.
Other types of AC failure, such as dislodgement, typically incur
lower costs than a CR-BSI; however, all require additional pro-
cedures for the insertion of a replacement device, with associated
costs for disposable equipment and labour.
Description of the intervention
A variety of dressings and securement devices are available for clin-
icians to use with ACs, and are designed to keep the AC safely in
place and free from complications. The earliest approach to keep-
ing all intravascular devices in place was the use of simple tape or
combined gauze and tape. Plastic film dressings emerged in the
1980s. Because these occlusive dressings trap skin moisture creat-
ing an ideal environment for the rapid growth of local microflora,
first-generation occlusive standard polyurethane (SPU) dressings
were later developed to be semipermeable to oxygen, carbon diox-
ide and water vapour (e.g. IV3000™, Smith and Nephew; Tega-
derm™, 3M) (Frasca 2010). SPU dressings are transparent, al-
lowing visual monitoring of the catheter insertion site. More re-
cently, bordered polyurethane (BPU) dressings have become avail-
able that retain the central transparent polyurethane component
of SPU dressings, with an additional external adhesive border to
maximise catheter security (e.g. Tegaderm™ I.V. Advanced, 3M).
The most common bacterial pathogens that result in hospital-ac-
quired CR-BSIs are coagulase-negative staphylococci, in partic-
ular Staphylococcus epidermidis and Staphylococcus aureus, which
are normal flora on human skin (Becker 2014; O’Grady 2002).
Dressing technology has respondedwith antimicrobial dressings in
which either the central dressing component is impregnated with
chlorhexidine gluconate (e.g. 3M™ Tegaderm™ CHG Dress-
ing) or circular chlorhexidine gluconate-impregnated sponges are
placed under the dressings (BIOPATCH®, Ethicon) and posi-
tioned around the insertion site. Alternative antimicrobial dress-
ings, including polyhexamethylene biguanide foam discs (e.g.
Kendall™ AMD Foam Disc), have been found to be safe to use
at catheter insertion sites (Webster 2017).
Securement of ACs was traditionally achieved by suturing the
catheter in place, prior to the application of a dressing (O’Grady
2011; Yamamoto 2002). Additional non-commercial options to
secure the AC include sterile or non-sterile tape in addition to a
dressing. Sutureless securement devices (SSDs) have become avail-
able commercially and are used in conjunction with transparent
dressings. Other dressings that incorporate a securement compo-
nent are designed to avoid the need for separate securement de-
vices, sutures or tape by combining a BPU-style dressing on the
skin with an additional adhesive securement affixed to the catheter
(e.g. SorbaView® SHIELD, Centurion). The use of tissue ad-
hesive has also been reported to provide additional securement
to SPU/BPU dressings (e.g. Histoacryl, BBraun) (Edwards 2014;
Reynolds 2015).
How the intervention might work
AC dressings and securement products have different but over-
lapping roles. The role of the AC dressing incorporates the pre-
vention of antimicrobial colonisation and CR-BSIs by providing
a protective barrier to stop skin flora from migrating from the
insertion site down the catheter tract, while also preventing con-
tamination of the catheter due to contact with hands and materi-
als (O’Grady 2011; Timsit 2011). Sutures, tapes and securement
devices are designed to ensure that ACs are neither partially nor
completely dislodged, to avoid losing functionality. Effective se-
curement should prevent movement within or out of the artery
(known as pistoning) by restricting movement or pressure on the
external part of the device which may result in catheter failure
and loss of blood pressure monitoring. It should also decrease the
incidence of forced removal or ‘drag’ from the infusion tubing,
and eliminate the risk of ‘catching’ on environmental structures
(Durie 2002; Naimer 2004).
In summary, the ideal AC dressing or securement device, or a
combination of the two, should: remain secured to the skin and
provide a protective barrier to prevent environmental microbial
AC contamination, colonisation and CR-BSIs; provide effective
securement to prevent AC failure from accidental removal, occlu-
sion, dislodgement and micro-motion; be comfortable for the pa-
tient; be easy to use (apply and remove); and be cost effective.
Why it is important to do this review
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Prevention of AC failure is a vital objective that prevents negative
impact on patient morbidity and mortality. The comparative ef-
fectiveness of dressings and securement methods remains uncer-
tain. There is no consensus on the optimal type of dressing or
method of securement to use with ACs, and this may reflect the
large number of products that are now available. Cochrane sys-
tematic reviews on the dressing and securement of both central
venous catheters and peripheral venous catheters have been pub-
lished (Gavin 2016; Marsh 2015; Ullman 2015). In contrast, the
comparative effectiveness of dressings and securement methods
designed for use with ACs is not well understood, with no pub-
lished Cochrane systematic reviews and few reported studies in-
vestigating AC dressing and securement (Edwards 2014; Reynolds
2015; Stephenson 2005).
O B J E C T I V E S
To compare the effectiveness of dressings and securement devices
for peripheral arterial catheters.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include published andunpublished randomised controlled
trials (RCTs) that evaluate the effect of different dressings and se-
curement methods on the protection and stabilisation of periph-
eral ACs. We will include controlled clinical trials (CCTs) if there
is an absence of RCTs. CCTs refer to quasi-randomised studies in
which an intervention and control are tested with concurrent en-
rolment and follow-up, butwithout strict randomisation (Lefebvre
2011). In order to minimise potential bias, we will include cross-
over trials only if they report outcome data at the conclusion of
the first treatment period, and will not include cluster-randomised
trials (Reeves 2013).
Types of participants
We will include any studies in which participants of any age re-
quired a peripheral AC (in the arm, leg or head) in any healthcare
setting. We will include all brands/types of peripheral AC.We will
exclude participants who had ACs inserted through skin burns
due to their predisposition to CR-BSIs and an altered skin surface
that limits the adhesiveness of dressing and securement products.
Types of interventions
We will include any trial comparing any type of dressing or se-
curement method with another type of dressing or securement
method for the protection or stabilisation of an AC. We will con-
sider dressings and devices that are made from any type of product
(e.g. polyurethane, gauze).
Dressings
• Gauze and tape





• Subcutaneous securement devices
• Combined dressing and securement products
• Tissue adhesive
• Sutures (stitches)
Types of outcome measures
Follow-up time for all outcomes will be until AC removal, with
the exception of CR-BSIs, which will be followed-up for 48 hours
post AC removal, as CR-BSIs occurring in this timeframe would
be considered to result from AC management if there is no other
source (Mermel 2009). We will record the duration of follow-up
for all outcome data.
Primary outcomes
• AC failure where the catheter has been removed due to
complications
• Incidence of CR-BSI, as defined by one of the following
criteria:
1. Primary bloodstream infection (BSI) (recognised pathogen in
the blood) with at least one positive blood culture from a periph-
eral vein and no other identifiable source for the BSI other than the
intravascular device (IVD), as well as either a positive semiquanti-
tative (> 15 colony-forming units (cfu)) or quantitative (> 103 cfu)
device culture, with the same organism (species and antibiogram)
isolated from the device and blood (Maki 2006; Mermel 2009;
O’Grady 2002).
2. Two blood cultures for a suspected CR-BSI, with paired blood
samples drawn from the catheter hub and a peripheral vein, that
both meet CR-BSI criteria for quantitative blood cultures (three-
fold greater colony count of growth for the same organism as from
the peripheral blood) or differential time to positivity (growth of
the samemicrobe from the catheter drawn blood at least two hours
before growth from the peripheral blood) (Mermel 2009); and
adverse events, including allergic reactions/skin injury related to
the different types of dressings and securements, local entry site
infection and phlebitis as described by the trial investigator.
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Secondary outcomes
• Dislodgement: partial or total dislodgement of the AC body
from the artery
• Occlusion, identified by inability to draw blood, infuse
flush solution or maintain an accurate trace to monitor blood
pressure
• Time to catheter failure
• Adverse events reported as number of participants in each
group with an event
• Participant satisfaction at study completion, using any
validated instrument (e.g. a visual analogue scale).
Search methods for identification of studies
Electronic searches
Wewill search the followingdatabases to retrieve reports of relevant
trials:
• the Cochrane Wounds Specialised Register (to date);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (to latest issue);
• Ovid MEDLINE (including In-Process & Other Non-
Indexed Citations, MEDLINE Daily and Epub Ahead of Print)
(from 1946 onwards);
• Ovid Embase (from 1974 onwards);
• EBSCO CINAHL Plus (Cumulative Index to Nursing and
Allied Health Literature Plus; from 1937 onwards).
We have devised a draft search strategy for CENTRAL which is
displayed in Appendix 2. We will adapt this strategy to search
Ovid MEDLINE, Ovid Embase and EBSCO CINAHL Plus.
We will combine the Ovid MEDLINE search with the Cochrane
Highly Sensitive Search Strategy for identifying randomised tri-
als in MEDLINE: sensitivity and precision-maximising version
(2008 revision) (Lefebvre 2011). We will combine the Embase
search with the Ovid Embase filter terms developed by the UK
Cochrane Centre (Lefebvre 2011).We will combine theCINAHL
Plus search with the randomised trials filter developed by the Scot-
tish Intercollegiate Guidelines Network (SIGN 2017). There will
be no restrictions with respect to language, study setting or date
of publication.
We will also search the following clinical trials registries for ongo-
ing and unpublished studies:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organisation International Clinical Trials
Registry Platform (ICTRP) (www.who.int/trialsearch);
• ISRCTN registry (www.isrctn.com/);
• Hong Kong Clinical Trials Register (
www.hkclinicaltrials.com);
• Indian Clinic Trials Registry (ctri.nic.in/Clinicaltrials/
login.php).
Searching other resources
We aim to identify other potentially eligible trials or ancillary pub-
lications by searching the reference lists of retrieved included trials
as well as relevant systematic reviews, meta-analyses and health
technology assessment reports. We will also contact experts in the
field and ask for information relevant to this review, and contact
dressing and securement device manufacturers, such as 3M, Smith
and Nephew, and Centurion, to access possible unpublished data
so as to avoid publication bias.
Data collection and analysis
Selection of studies
Two review authors (HR and AU) will independently assess the
titles and abstracts of the citations retrieved from the searches for
relevance. Following an initial assessment, we will retrieve full-text
versions of all the potentially eligible studies and the same review
authors will continue independent review, checking these papers
for eligibility. We will resolve discrepancies between the review
authors by discussion. If differences of opinion can not be resolved
by consensus, we will consult a third independent review author
(EA). We will include a list of all studies including exclusions
and reasons for exclusion, in the review in order to maintain a
transparent approach, using a PRISMA flowchart (Liberati 2009).
If studies have been reported in multiple publications, we will
extract data from all the reports to ensure we capture all available
and relevant data; however, we will include such studies only once
in the review.
Data extraction and management
We will extract and summarise details from the eligible studies us-
ing a data extraction sheet. Two review authors (HR and AU) will
perform independent data extraction using a predesigned check-
list, followed by cross-checking for accuracy and agreement. We
will resolve any discrepancies through discussion and arbitration
by a third review author, as necessary. For any studies reported
in duplicate publications, we will extract the maximum amount
of data from all relevant publications. We will make attempts to
contact the authors to retrieve any missing data. We will include
RCTs that are reported only in abstract form provided the avail-
able data are sufficient for reasonable extraction from either the
abstract or the study authors.
For studies with more than two intervention arms, we will extract
only data from intervention and control groups that meet our
eligibility criteria.
We intend to extract the following data:
• bibliographic data;
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• participant characteristics including age, sex/gender, culture
and socioeconomic status, and specified inclusion and exclusion
criteria;
• country of origin;
• study dates;
• setting;
• type of AC;
• type of dressing, securement device, or both;





• number of participants randomised to each trial arm and
number included in final analysis;
• duration of treatment;
• outcomes;
• duration of follow-up;
• number of withdrawals by group;
• information regarding ethics approval, consent and declared
conflicts of interest;
• publication status; and
• source of funding.
Assessment of risk of bias in included studies
Two review authors (HR and AU) will independently perform an
assessment of quality and bias for each eligible study using the
Cochrane Handbook for Sytematic Reviews of Interventions ’Risk of
bias’ assessment tool (Appendix 3). We will assess seven specific
domains, namely sequence generation, allocation concealment,
blinding of participants andpersonnel, blinding of outcome assess-
ment, incomplete outcome data, selective outcome reporting, and
other issues that potentially may bias the study (Higgins 2011a).
Wewill complete a ’Risk of bias’ table for all eligible studies.Where
information on risk of bias relates to unpublished data or corre-
spondence with trialists, we will note this in the ’Risk of bias’ ta-
ble. We will perform separate assessments of blinding and com-
pleteness of outcome data for self-reported and objective outcome
measures. We will resolve any differences or discrepancies between
the review authors (HR and AU) through discussion. If consensus
is not reached, we will consult a third independent review author
(EA).We will present our findings and judgements in two ’Risk of
bias’ summary figures. One of the summary figures will be a sum-
mary of bias for each item across all studies; the second summary
figure will show a cross tabulation of each study by all ’Risk of
bias’ items. This presentation of internal validity will indicate the
weight that can be given to the results of each study. We anticipate
that blinding of participants and clinical staff may not be possible
in many of the comparisons; however, some blinded outcome as-
sessments, such as CR-BSI, may still be possible.
Measures of treatment effect
We will calculate risk ratio (RR) for dichotomous outcomes and
mean differences (MD) for continuous outcomes. Where final
and change scores are reported for continuous outcomes, we will
give the final score preference over change score. When outcomes
are measured on ordinal scales, we will convert these to continu-
ous data and analyse the data using standardised mean differences
(SMD) (Anzures-Cabrera 2011). We may encounter the use of
different tools to measure the same outcome (e.g. skin damage).
We will collect data only from studies that use a standard assess-
ment tool, and will use the SMD as the summary statistic in any
meta-analysis of such data.We will present treatment comparisons
with 95% confidence intervals (CI). We will analyse time to event
(e.g. time to the development of an occlusion). We will analyse
time-to-event data as hazard ratios and we will calculate the hazard
ratios where they are not reported, but calculable (Parmar 1998;
Tierney 2007)
Unit of analysis issues
We do not anticipate any unit of analysis issues, expecting that
the RCTs and CCTs included will have randomised participants
and not ACs. For studies in which ACs and not participants have
been randomised, wewill include only the first AC per participant.
We will include only those cross-over trials with outcome data re-
ported at the conclusion of the first treatment period. We will not
include cluster-randomised trials. In studies where two or more
interventions are used in one treatment arm (e.g. tissue adhesive
plus polyurethane dressing), we will analyse this as a combined in-
tervention. If individuals undergo more than one intervention or
there aremultiple observations for the same outcome (e.g. repeated
measurements and recurring events), we will contact the study au-
thors for participant- and device-level data and then performmul-
tilevel regression to calculate the adjusted effect. If additional data
are unavailable we will exclude such studies frommeta-analysis. In
accordance with Higgins 2011b, for included studies that involve
the comparison of multiple interventions using a single control,
we will split the ’shared’ control group to avoid additional unit of
analysis issues. This is to distribute the appropriate study weight
and maintain independent comparisons fairly. To prevent unit of
analysis errors, participant satisfaction data will be included at the
time of study completion only (i.e. not repeated observations). We
will undertake time-to-event analyses for the outcome of catheter
failure as hazard ratios.
Dealing with missing data
The existence of missing data may be due to the exclusion of par-
ticipants from analysis post-randomisation or participants lost to
follow-up. This potentially introduces bias into the trial.When the
evidence shows that data are missing, we will make every attempt
to contact the study authors to request the missing information. If
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the required data are not supplied after multiple attempts, we will
analyse only the available data. Where measures of variance are
missing, we will calculate these where possible (Higgins 2011a).
If we are not able to calculate measures of variance, we will doc-
ument this, but exclude from the meta-analysis. We will consider
the impact of the missing data on the findings of the review in
the discussion. If there are sufficient data, we will investigate the
impact of missing data using a sensitivity analysis, excluding the
studies with missing data to assess how this will affect the results.
Assessment of heterogeneity
We will undertake an assessment of comparability of the studies
with regard to clinical, methodological and statistical heterogene-
ity prior to meta-analysis. We will visually inspect the meta-an-
alytic model, and consider the Chi2 and I2 statistics in order to
assess the likelihood that the variance across the studies is due to
heterogeneity rather than chance (Higgins 2003). If we find sig-
nificant heterogeneity using these criteria, we will explore hetero-
geneity through subgroup and sensitivity analyses (including and
excluding outlying studies). An I2 statistic of more than 50% may
represent moderate heterogeneity, and a value of 0 to 40% may
suggest that heterogeneity is not important (Kontopantelis 2012;
Kontopantelis 2013; Ryan 2016). If the level of these statistics
cannot be improved through subgroup or sensitivity analyses, with
the P value of the Chi2 test being less than 0.1 or the I2 statistic
greater than 50%, we will consider not performing ameta-analysis
(Higgins 2011a; Higgins 2011b). The importance of the observed
value of the I2 statistic depends on the magnitude and direction
of effects and the strength of evidence for heterogeneity (e.g. the P
value from the Chi2 test, or a confidence interval for the I2 statis-
tic).
Assessment of reporting biases
Wewill use funnel plots to assess reporting bias usingReviewMan-
ager 5 (RevMan 5) (Review Manager 2014) if sufficient studies
(at least 10 RCTs) are included in a meta-analysis. We will visu-
ally inspect a funnel plot for asymmetry, and will test funnel plot
asymmetry statistically using a linear regression test (Egger 1997).
A P value of less than 0.1 could be an indication of publication
bias or small study effects.
Data synthesis
We will combine details of included studies in a narrative review
according to the type of comparator, possibly by location/type of
wound and then by outcomes. We will consider the clinical and
methodological heterogeneity andundertake poolingwhen studies
appear appropriately similar in terms of wound type, intervention
type, duration of follow-up and outcome type.
In terms of meta-analytical approach, we are unable to pre specify
the amount of clinical, methodological and statistical heterogene-
ity in the included studies, but it might be extensive. Thus, we an-
ticipate using a random-effects approach for meta-analysis. Con-
ducting meta-analysis with a fixed-effect model in the presence of
even minor heterogeneity may provide overly narrow confidence
intervals. We will use a fixed-effect approach only when we as-
sess clinical and methodological heterogeneity to be minimal, and
the assumption that a single underlying treatment effect is being
estimated holds. We will use the Chi2 and I2 statistics to quan-
tify heterogeneity but we will not use them to guide the choice
of model for meta-analysis. We will exercise caution when meta-
analysed data are at risk of small study effects, because a random-
effects model may be unsuitable. In this case, or where there are
other reasons to question the selection of a fixed-effect or random-
effects model, we will assess the impact of the approach using sen-
sitivity analyses to compare results from the alternate models. We
will report any evidence that suggests that the use of a particular
model might not be robust. We may conduct meta-analyses even
when we think there is extensive heterogeneity. We will attempt
to explore the causes behind any heterogeneity using meta-regres-
sion, if possible (Thompson 1999).
We will present data using forest plots, where possible. For di-
chotomous outcomeswewill present summary estimates as risk ra-
tio (RR) with 95% confidence intervals (CIs). Where continuous
outcomes are measured in the same way across studies, we plan to
present pooled mean difference (MDs) with 95% CIs; we plan to
pool standardised mean difference (SMD) estimates where studies
measure the same outcome using different methods. For time-to-
event data, we plan to plot (and, if appropriate, pool) estimates of
hazard ratios and 95% CIs as presented in the study reports using
the generic inverse variance method in RevMan (Review Manager
2014). Where time to healing is analysed as a continuous measure
but it is not clear whether all wounds healed, we will document
the use of the outcome in the study but we will not summarise
data and not subject it to meta-analysis.
Wewill obtain pooled estimates of treatment effects usingRevMan
(Review Manager 2014).
’Summary of findings’ tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality, clinical importance and context of the evidence, the
magnitude of the effects of the interventions examined and the
sumof available data for themain outcomes (Schünemann 2011a).
’Summary of findings’ tables also include an overall grading of the
evidence relating to each of the main outcomes using the GRADE
approach. This approach defines the quality of a body of evidence
regarding the extent towhich one can be confident that an estimate
of effect or association is close to the true quantity of specific
interest. The quality of a body of evidence involves consideration
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of within trial risk of bias (methodological quality), directness
of evidence, heterogeneity, precision of effect estimates and risk
of publication bias (Schünemann 2011b). We will present the
following outcomes in the ’Summary of findings’ tables:
• AC failure
• incidence of CR-BSI
• adverse events
Subgroup analysis and investigation of heterogeneity
We will assess heterogeneity across the subgroups listed below and
conduct subgroup analyses to investigate differences between the
subgroups.Wewill perform a standard test for heterogeneity across
subgroup results rather than across individual study results. We
will use a fixed-effect inverse-variance weighted average approach
for meta-analysis, which is equivalent to the test described by
Deeks 2001. We will also compute the I2 statistic for subgroup
differences:
• adult participants versus paediatric participants versus
neonatal participants;
• AC dwelling (less than 48 hours versus 48 hours or longer):
if participants require ACs for more than 48 hours, this suggests
higher acuity, with increased needs for securing devices in
relation to physical status (e.g. increased perspiration making
dressing adhesion difficult); there also may be a greater infection
risk over time;
• ACs inserted in the operating theatre as part of a surgical
procedure versus those inserted in intensive care. Operating
theatre-inserted ACs may be subject to different forces requiring
different methods of securement to those inserted in an ICU
(e.g. people undergoing surgery are initially immobile, are then
transferred within the hospital and have ACs removed within 1
to 2 days, whereas those in the ICU remain immobile and
usually require an AC for longer);
• winged versus non-winged AC designs. Some ACs have
plastic tabs/wings extending from the sides of the catheter and
this may impact on the effectiveness of securement method
Sensitivity analysis
We will test our protocol for the impact of the following study
characteristics in sensitivity analyses:
• study size (less than or greater than 100 participants); small
studies of less than 100 participants will be removed to assess the
contribution to overall effect size.
• studies classified as having ’high’ risk of selection bias,
reported as ’high’ bias within either randomisation or allocation
concealment, will be removed to assess the influence on the
results;
• missing data, with consideration of best (all missing cases
failed in control group and not failed in intervention group) and
worst (all missing cases failed in intervention group and not
failed in control group) case scenarios;
• use of a fixed-effect versus a random-effects model.
Elements of this Methods section are modelled on the standard
Cochrane Wounds Protocol Template.
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A P P E N D I C E S
Appendix 1. Glossary of terms
Antimicrobial: destroying or inhibiting the growth of microorganisms.
Arterial catheter: a thin flexible plastic tube that is inserted into an artery for easy access to the bloodstream for medical uses.
Arterial thrombosis: blood clot that forms in an artery.
Axillary artery: a major artery of the upper arm.
Brachial artery: a major artery of the upper arm.
Central venous catheter: a long, thin, flexible tube used to give medicines, fluids, nutrients, or blood products inserted in the arm or
chest into a large vein for use in critical care or for long term therapy.
Distal digits: fingers, thumbs and toes.
Dorsalis pedis artery: the artery which provides the main blood supply to the foot.
Femoral artery: a major artery of the thigh.
Occlusion: blockage of a blood vessel or device.
Peripheral: distal parts of the limbs where venous and arterial catheters may be inserted.
Microorganisms: small living organisms such as bacteria, fungi and viruses that are only visible under a microscope.
Radial artery: the main artery in the lateral aspect of the forearm.
Securement: a device to keep intravascular catheters in place, preventing accidental removal.
Vascular: relating to blood vessels.
Venous catheter: a thin flexible plastic tube that is inserted into a vein for therapy such as medications and fluids.
Appendix 2. The Cochrane Central Register of Controlled Trials (CENTRAL) draft search strategy
#1 MeSH descriptor: [Catheterization, Peripheral] explode all trees
#2 MeSH descriptor: [Catheters] explode all trees
#3 (arteri* near/3 catheter*):ti,ab,kw
#4 (arteri* next line*):ti,ab,kw
#5 (vascular next access next device*):ti,ab,kw
#6 (vascular near/3 catheter*):ti,ab,kw
#7 (“vascular access”):ti,ab,kw
#8 {or #1-#7}
#9 MeSH descriptor: [Bandages] explode all trees
#10 MeSH descriptor: [Hydrogels] explode all trees
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#11 MeSH descriptor: [Alginates] explode all trees
#12 MeSH descriptor: [Silver] explode all trees
#13 MeSH descriptor: [Silver Sulfadiazine] explode all trees
#14 MeSH descriptor: [Honey] explode all trees
#15 MeSH descriptor: [Polyurethanes] explode all trees
#16 MeSH descriptor: [Tissue Adhesives] explode all trees
#17 MeSH descriptor: [Chlorhexidine] explode all trees
#18 MeSH descriptor: [Sutures] explode all trees
#19 (dressing* or hydrocolloid* or alginate* or hydrogel* or “foam” or “bead” or “film” or “films” or tulle or gauze or non-adherent or
“non adherent” or silver or honey or matrix):ti,ab,kw
#20 (securement next device*):ti,ab,kw
#21 (securement next method*):ti,ab,kw
#22 ((standard or border*) near/2 (polyurethane*)):ti,ab,kw
#23 (chlorhexidine or CHG) near/4 dressing*:ti,ab,kw
#24 (SSD or SPU or BPU or CGI):ti,ab,kw
#25 (Tegaderm or Opsite or Statlock or “Grip-Lok” or Histacryl or “I.V. Advanced” or SorbaView or Centurion or BIOPATCH):
ti,ab,kw
#26 ((tissue* or skin) next (adhesive* or glue)):ti,ab,kw
#27 ((sutur* or stitch* or closure or close or closing*) near/3 (securement*)):ti,ab,kw
#28 {or #9-#27}
#29 {and #8, #28} in Trials
Appendix 3. Assessment of risk of bias
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random-number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process provided to permit a judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
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High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: use of an open random allocation schedule (e.g. a list of random numbers); assignment envelopes used without appropriate
safeguards (e.g. envelopes were unsealed, non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Unclear
Insufficient information provided to permit a judgement of low or high risk of bias. This is usually the case if themethod of concealment
is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement were not likely to have been
influenced by lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others was unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement was likely to have been influenced by lack of
blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken and the
outcome or outcome measurement was likely to have been influenced by lack of blinding.
• Either participants or some key study personnel were not blinded, and the non-blinding was likely to introduce bias.
Unclear
Either of the following.
• Insufficient information provided to permit a judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following.
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have
a clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes was not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
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High risk of bias
Any one of the following.
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes was enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following.
• Insufficient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomised not
stated, no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following.
• The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the
review have been reported in the prespecified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were prespecified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following.
• Not all of the study’s prespecified primary outcomes have been reported.
• One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not prespecified.
• One or more reported primary outcomes of the study were not prespecified (unless clear justification for their reporting is
provided, such as an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information provided to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into
this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
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High risk of bias
There is at least one important additional risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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